Lawrence Corey

Q: What Schools Are Affiliated With Lawrence Corey

Lawrence Corey is affiliated with the following schools: University of Amsterdam, University of Alberta, University of Michigan, University of California, San Diego, University of California, Los Angeles, University System of Maryland, University of Colorado, University of Washington, University of Pittsburgh, University of Geneva, Duke University

Lawrence Corey's AcademicInfluence.com Rankings

Lawrence Corey

Biology

#2267

World Rank

#3623

Historical Rank

#1015

USA Rank

Virology

#32

World Rank

#34

Historical Rank

#14

USA Rank

Immunology

#79

World Rank

#85

Historical Rank

#29

USA Rank

biology Degrees

Download Badge

Biology

Why Is Lawrence Corey Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Research and career In the early 1980s, Corey worked with Nobel Prize-winning biochemist and pharmacologist Dr. Gertrude Elion to demonstrate that an antiviral that was selective and specific for a viral-specified enzyme could be safely and effectively administered to control a chronic viral infection . Corey first conceived of, demonstrated the core concepts and directed line association between quantitative viral load reduction and clinical benefit using topical, intravenous and oral formulations of acyclovir in classic studies performed between 1980 and 1984. Acyclovir was the first antiviral drug to get rapid approval from the FDA, and it was Corey's studies that defined its use in genital herpes. These studies led to the licensure for acyclovir in a wide variety of infections such as HSV-1, HSV-2 and varicella chickenpox virus, including the first use of an antiviral for daily long term use. Acyclovir and its derivatives valacyclovir and famciclovir are the most prescribed antivirals in the world: over 400 million people have HSV-2 infection. These early studies prompted the subsequent successful involvement of the pharmaceutical and medical sciences communities to develop effective antiviral therapy for HIV and Hepatitis B.

(See a Problem?)

Lawrence Corey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (2020) (5634)
Clinical and Epidemiologic Features of Primary HIV Infection (1996) (3365)
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial (2008) (1743)
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. (2002) (1370)
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 (2021) (1283)
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. (2002) (935)
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. (1998) (841)
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis (2008) (750)
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. (1996) (739)
The acquisition of herpes simplex virus during pregnancy. (1997) (721)
Infections with herpes simplex viruses (1). (1986) (688)
Once-daily valacyclovir to reduce the risk of transmission of genital herpes* (2004) (612)
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. (2003) (602)
Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. (1997) (586)
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. (2002) (581)
T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients (1996) (579)
The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics (2004) (572)
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. (2000) (553)
Plasma viremia in human immunodeficiency virus infection. (1989) (552)
Vaccine prevention of maternal cytomegalovirus infection. (2009) (542)
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. (2013) (536)
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera (1988) (516)
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial (2021) (501)
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants (2000) (499)
Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. (2000) (494)
Combination antifungal therapy for invasive aspergillosis. (2004) (488)
Mucosal shedding of human herpesvirus 8 in men. (2000) (485)
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. (1999) (481)
Risk factors for the sexual transmission of genital herpes. (1992) (471)
Modeling plasma virus concentration during primary HIV infection. (2000) (460)
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. (1999) (458)
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. (2001) (453)
Virologic characteristics of subclinical and symptomatic genital herpes infections. (1995) (443)
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial (2008) (441)
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. (2004) (433)
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy (1999) (420)
Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. (1991) (418)
A strategic approach to COVID-19 vaccine R&D (2020) (411)
Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. (1987) (405)
Adenovirus infections in patients undergoing bone-marrow transplantation. (1985) (405)
Genital ulceration as a risk factor for human immunodeficiency virus infection. (1988) (390)
A population-based study of primary human herpesvirus 6 infection. (2005) (390)
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. (2002) (384)
Predictors of morbidity and mortality in neonates with herpes simplex virus infections (1991) (370)
Persistence of HIV-1 Receptor-Positive Cells after HSV-2 Reactivation: A Potential Mechanism for Increased HIV-1 Acquisition (2009) (368)
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. (1997) (366)
In vivo migration and function of transferred HIV-1-specific cytotoxic T cells (1999) (361)
Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. (2004) (358)
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. (2005) (351)
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein (1991) (335)
Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. (1998) (331)
Evidence for Human Immunodeficiency Virus Type 1 Replication In Vivo in CD14+ Monocytes and Its Potential Role as a Source of Virus in Patients on Highly Active Antiretroviral Therapy (2002) (325)
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. (2001) (320)
Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation (2007) (319)
Biological and Virologic Characteristics of Primary HIV Infection (1998) (317)
Comparison of Real-Time PCR Assays with Fluorescent-Antibody Assays for Diagnosis of Respiratory Virus Infections in Children (2006) (315)
Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. (2011) (314)
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. (1984) (313)
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. (1998) (313)
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. (2011) (310)
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine (2021) (308)
Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. (1982) (304)
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. (1997) (303)
Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. (1993) (302)
Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. (1981) (300)
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. (2003) (295)
Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. (2005) (294)
Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission (2011) (294)
Changing presentation of herpes simplex virus infection in neonates. (1988) (290)
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. (1998) (279)
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase (2021) (278)
Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. (2001) (271)
Infections with herpes simplex viruses. (Second of two parts) (1986) (270)
Optimization of Quantitative Detection of Cytomegalovirus DNA in Plasma by Real-Time PCR (2004) (267)
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. (1991) (258)
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. (2010) (257)
Frequent detection of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. (1997) (257)
Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research (2003) (255)
Suppression of Subclinical Shedding of Herpes Simplex Virus Type 2 with Acyclovir (1996) (255)
Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations (1994) (255)
Genital herpes and public health: addressing a global problem. (2000) (255)
Therapy of herpes zoster with oral acyclovir. (1988) (254)
Genital Herpes Has Played a More Important Role than Any Other Sexually Transmitted Infection in Driving HIV Prevalence in Africa (2008) (254)
A trial of topical acyclovir in genital herpes simplex virus infections. (1982) (252)
Effects on infants of a first episode of genital herpes during pregnancy. (1987) (248)
Herpes Simplex Virus Inhibits Apoptosis through the Action of Two Genes, Us5 and Us3 (1999) (243)
Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. (2002) (242)
Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. (1998) (242)
Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. (1989) (241)
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. (1997) (239)
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. (1989) (237)
Frequency of Acquisition of First‐episode Genital Infection with Herpes Simplex Virus from Symptomatic and Asymptomatic Source Contacts (1985) (237)
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. (2003) (237)
Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. (1994) (233)
Brief Communication: Fatal Human Metapneumovirus Infection in Stem-Cell Transplant Recipients (2006) (229)
Genetic impact of vaccination on breakthrough HIV-1 sequences from the Step trial (2011) (229)
Immune Surveillance by CD8αα+ Skin Resident T Cells in Human Herpesvirus Infection (2013) (228)
Herpes simplex: insights on pathogenesis and possible vaccines. (2008) (218)
Development of a High-Throughput Quantitative Assay for Detecting Herpes Simplex Virus DNA in Clinical Samples (1999) (215)
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. (2011) (214)
Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. (2004) (213)
Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes (1994) (212)
Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. (2001) (210)
Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. (2003) (210)
Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. (1988) (208)
CHANGES IN PLASMA HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RNA ASSOCIATED WITH HERPES SIMPLEX VIRUS REACTIVATION AND SUPPRESSION (2002) (207)
Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. (2007) (202)
Cytomegalovirus reactivation in critically ill immunocompetent patients. (2008) (202)
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. (1998) (201)
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). (2012) (200)
Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features (1995) (200)
Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. (2007) (199)
Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma (1997) (199)
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. (2008) (198)
After the pandemic: perspectives on the future trajectory of COVID-19 (2021) (197)
Maternal and neonatal herpes simplex virus infections. (2009) (197)
Application of the Polymerase Chain Reaction to the Diagnosis and Management of Neonatal Herpes Simplex Virus Disease (1996) (195)
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. (1993) (195)
Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. (2001) (193)
A framework for assessing immunological correlates of protection in vaccine trials. (2007) (192)
Activation of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Lytic Replication by Human Cytomegalovirus (2001) (191)
Intravenous acyclovir for the treatment of primary genital herpes. (1983) (191)
Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. (2002) (190)
Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk (2010) (189)
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. (2007) (188)
Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. (1989) (187)
SARS-CoV-2 Variants in Patients with Immunosuppression. (2021) (186)
Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. (2003) (184)
Underdiagnosis of Genital Herpes by Current Clinical and Viral-Isolation Procedures (1992) (182)
Chronic fatigue. A prospective clinical and virologic study. (1990) (180)
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies (2015) (179)
Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. (1998) (179)
Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. (2001) (176)
Immune correlates of vaccine protection against HIV-1 acquisition (2015) (175)
Treatment of Recurrent Genital Herpes Simplex Infections With Oral Acyclovir: A Controlled Trial (1984) (174)
Infection of Macaca nemestrina by human immunodeficiency virus type-1. (1992) (174)
Cyclophosphamide metabolism is affected by azole antifungals. (2004) (173)
Prospects for a safe COVID-19 vaccine (2020) (173)
DIFFERENCE BETWEEN HERPES SIMPLEX VIRUS TYPE I AND TYPE 2 NEONATAL ENCEPHALITIS IN NEUROLOGICAL OUTCOME (1988) (172)
Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. (2000) (172)
Dual HIV-1 infection associated with rapid disease progression (2004) (172)
Comprehensive Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Gamma Interferon-Secreting CD8+ T Cells in Primary HIV-1 Infection (2003) (171)
Treatment of Refractory BK Virus‐Associated Nephropathy With Cidofovir (2003) (170)
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. (2007) (170)
Comparison of viral isolation, direct immunofluorescence, and indirect immunoperoxidase techniques for detection of genital herpes simplex virus infection (1981) (169)
Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. (1997) (168)
High‐Throughput Quantitative Analysis of Hepatitis B Virus DNA in Serum Using the TaqMan Fluorogenic Detection System (2000) (168)
Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial (1998) (168)
Enhanced: The Need for a Global HIV Vaccine Enterprise (2003) (168)
Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. (1999) (167)
Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. (1999) (166)
A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy (1995) (163)
BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. (2005) (161)
Assessment of Hepatitis C Viremia Using Molecular Amplification Technologies: Correlations and Clinical Implications (1995) (159)
Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. (2003) (159)
Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients (1996) (159)
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
Cytomegalovirus infection in sex partners: evidence for sexual transmission. (1985) (158)
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. (1999) (157)
Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. (1994) (157)
Persistence in the population: epidemiology, transmission (2007) (156)
Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. (2000) (154)
A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. (2003) (154)
Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals (1993) (154)
The Frequency of Unrecognized Type 2 Herpes Simplex Virus Infection Among Women Implications for the Control of Genital Herpes (1990) (153)
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. (2004) (153)
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. (2000) (153)
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. (2001) (153)
Evolution of Hepatitis C Virus Quasispecies in Hypervariable Region 1 and the Putative Interferon Sensitivity-Determining Region during Interferon Therapy and Natural Infection (1998) (152)
Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. (1997) (152)
Association between cervical shedding of herpes simplex virus and HIV-1 (2002) (152)
Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. (2010) (151)
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico (2021) (151)
Airflow Decline after Myeloablative Allogeneic Hematopoietic Cell Transplantation: The Role of Community Respiratory Viruses (2006) (151)
Functional Analysis of the Human Cytomegalovirus US28 Gene by Insertion Mutagenesis with the Green Fluorescent Protein Gene (1998) (150)
Chlamydia pneumoniae, Herpes Simplex Virus Type 1, and Cytomegalovirus and Incident Myocardial Infarction and Coronary Heart Disease Death in Older Adults: The Cardiovascular Health Study (2000) (149)
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. (2021) (148)
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204) (2011) (148)
Natural History of Genital Herpes Simplex Virus Type 1 Infection (2003) (147)
Divergent patterns of progression to AIDS after infection from the same source: human immunodeficiency virus type 1 evolution and antiviral responses (1997) (146)
CD27 Expression Promotes Long-Term Survival of Functional Effector–Memory CD8+Cytotoxic T Lymphocytes in HIV-infected Patients (2004) (146)
Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. (1999) (145)
Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. (1991) (145)
Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy (1998) (145)
Immune Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial (2021) (144)
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. (2008) (143)
Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. (2002) (143)
Quantitative Stability of DNA after Extended Storage of Clinical Specimens as Determined by Real-Time PCR (2002) (142)
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. (1997) (142)
Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. (2012) (142)
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. (2001) (141)
The Relationship between Condom Use and Herpes Simplex Virus Acquisition (2005) (141)
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. (2001) (140)
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. (2001) (140)
Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions (1994) (140)
Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. (1991) (139)
The management of pregnancies complicated by genital infections with herpes simplex virus. (1992) (139)
Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial (2010) (138)
Selection on the Human Immunodeficiency Virus Type 1 Proteome following Primary Infection (2006) (136)
Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection (1993) (134)
Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. (2004) (133)
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. (1992) (133)
Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. (1999) (133)
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. (1992) (133)
Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. (2004) (133)
The current trend in genital herpes. Progress in prevention. (1994) (133)
Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. (2011) (132)
Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia (2003) (132)
HSV and Glycoprotein J Inhibit Caspase Activation and Apoptosis Induced by Granzyme B or Fas1 (2001) (130)
CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells1 (2001) (128)
Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. (1991) (127)
Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory (1992) (126)
Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding (2015) (125)
Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. (2008) (124)
Detection of Epstein-Barr Virus DNA in Sera from Transplant Recipients with Lymphoproliferative Disorders (1999) (123)
Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. (2001) (123)
Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. (2001) (122)
The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy (2003) (120)
USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. USPHS/IDSA Prevention of Opportunistic Infections Working Group. (1995) (120)
Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis. (1983) (120)
Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to Cytotoxic T-Lymphocyte-Induced Apoptosis (1998) (119)
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens (1992) (119)
HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. (2011) (118)
Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women (1994) (118)
Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population (1987) (117)
Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. (2004) (117)
BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. (2004) (115)
Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial (2007) (115)
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. (2001) (115)
Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. (1998) (115)
Diminished Interferon-γ and Lymphocyte Proliferation in Neonatal and Postpartum Primary Herpes Simplex Virus Infection (1992) (114)
Helicase-primase inhibitor pritelivir for HSV-2 infection. (2014) (114)
Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. (1990) (114)
Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. (2000) (113)
HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. (2012) (112)
Pharmacokinetics of acyclovir in the term human pregnancy and neonate. (1991) (112)
Synergistic copathogens--HIV-1 and HSV-2. (2007) (112)
A Randomized, Placebo-Controlled Comparison of Oral Valacyclovir and Acyclovir in Immunocompetent Patients With Recurrent Genital Herpes Infections (1998) (112)
Pharmacokinetic disposition of zidovudine during pregnancy. (1991) (112)
Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences. (1982) (111)
Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients (2009) (111)
Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. (2001) (111)
HIV vaccines: new frontiers in vaccine development. (2006) (110)
Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. (2002) (110)
Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes (2010) (110)
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials (2012) (109)
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. (2014) (109)
Mortality Rates of Human Metapneumovirus and Respiratory Syncytial Virus Lower Respiratory Tract Infections in Hematopoietic Cell Transplantation Recipients (2013) (109)
The Use of Nonhuman Primate Models in HIV Vaccine Development (2008) (108)
Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. (2005) (107)
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. (2007) (107)
Frequent Release of Low Amounts of Herpes Simplex Virus from Neurons: Results of a Mathematical Model (2009) (106)
Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. (1987) (106)
Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real‐time taqman PCR assay (2005) (106)
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. (2001) (106)
Herpes simplex virus-2 infection. An emerging disease? (1998) (106)
High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes (1996) (105)
Diversity of the CD8+ T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes (2006) (105)
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. (2006) (105)
Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients (1997) (103)
Chronic fatigue in adolescents. (1991) (103)
Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. (2007) (102)
Neonatal Herpes Simplex Virus Infection in King County, Washington: Increasing Incidence and Epidemiologic Correlates (1983) (101)
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection (1992) (100)
Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. (1988) (100)
Virus Population Homogenization following Acute Human Immunodeficiency Virus Type 1 Infection (2002) (100)
Detection and quantification of human metapneumovirus in pediatric specimens by real-time RT-PCR (2005) (99)
Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. (2000) (99)
Clinical Outcomes Associated With Respiratory Virus Detection Before Allogeneic Hematopoietic Stem Cell Transplant (2015) (98)
Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. (2010) (98)
Herpesvirus infections in persons infected with human immunodeficiency virus. (1995) (98)
Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. (1998) (98)
Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. (2007) (97)
Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial (2017) (96)
The need and challenges for development of an Epstein-Barr virus vaccine. (2013) (96)
Persistence of Extraordinarily Low Levels of Genetically Homogeneous Human Immunodeficiency Virus Type 1 in Exposed Seronegative Individuals (2003) (95)
Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. (2015) (95)
Viral Linkage in HIV-1 Seroconverters and Their Partners in an HIV-1 Prevention Clinical Trial (2011) (94)
Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation (1999) (94)
HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. (2000) (93)
Tipping the scales of herpes simplex virus reactivation: The important responses are local (1998) (93)
Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy. (1983) (92)
Protocol for Detection of Biofilms on Needleless Connectors Attached to Central Venous Catheters (2001) (92)
Characteristics of HIV-1 Discordant Couples Enrolled in a Trial of HSV-2 Suppression to Reduce HIV-1 Transmission: The Partners Study (2009) (92)
Fertility parameters in men infected with human immunodeficiency virus. (1991) (91)
Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A (2002) (91)
Cellular immune response in genital herpes simplex virus infection. (1978) (90)
Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. (2007) (90)
Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes. (1993) (90)
Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. (1997) (90)
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. (1998) (89)
Compartmentalization of Human Immunodeficiency Virus Type 1 between Blood Monocytes and CD4+ T Cells during Infection (2004) (89)
Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. (2008) (89)
Viremia in neonatal herpes simplex virus infections. (1999) (89)
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection (2013) (89)
Shedding of human herpesvirus 8 in oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan women. (2004) (88)
High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron (2021) (88)
Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. (1996) (87)
Genital herpes in pregnancy: risk factors associated with recurrences and asymptomatic viral shedding. (1985) (87)
Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation (2009) (87)
Genital Herpes in a Primary Care Clinic: Demographic and Sexual Correlates of Herpes Simplex Type 2 Infections (1997) (87)
Reactivities of human sera with human herpesvirus-8-infected BCBL-1 cells and identification of HHV-8-specific proteins and glycoproteins and the encoding cDNAs. (1998) (86)
Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. A population-based case-control study. (1994) (86)
Genital shedding of herpes simplex virus among men. (2002) (86)
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. (2011) (85)
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. (2002) (84)
Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. (1990) (84)
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (2022) (83)
Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? (2002) (83)
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials (2017) (83)
Humoral immune response to HSV‐1 and HSV‐2 viral proteins in patients with primary genital herpes (1985) (82)
Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes (1992) (82)
Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection (1993) (82)
Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. (1993) (82)
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. (1997) (81)
Coinfection with human herpesvirus 6 variants A and B in lung tissue (1996) (81)
Phase I Study of Cellular Adoptive Immunotherapy Using Genetically Modified CD8+ HIV-Specific T Cells for HIV Seropositive Patients Undergoing Allogeneic Bone Marrow Transplant. Fred Hutchinson Cancer Research Center and the University of Washington (1992) (79)
Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. (2003) (79)
Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor (1996) (79)
Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi’s Sarcoma (1998) (79)
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Adults (2021) (79)
Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. (2007) (79)
A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. (2006) (77)
Optimizing PCR Positivity Criterion for Detection of Herpes Simplex Virus DNA on Skin and Mucosa (2007) (77)
Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance. (2007) (77)
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials (2020) (77)
Respiratory Virus Pneumonia after Hematopoietic Cell Transplantation (HCT): Associations between Viral Load in Bronchoalveolar Lavage Samples, Viral RNA Detection in Serum Samples, and Clinical Outcomes of HCT (2010) (77)
Acyclovir prophylaxis for herpes simplex virus infection (1987) (76)
Herpes simplex virus viremia during primary genital infection. (2008) (76)
Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. (2002) (76)
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. (1999) (76)
Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. (1986) (75)
Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. (2007) (75)
Selection for Human Immunodeficiency Virus Type 1 Recombinants in a Patient with Rapid Progression to AIDS (2002) (75)
The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro (2011) (75)
Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen (1998) (75)
Sensitive Method for Detection of Human Herpesviruses 6 and 7 in Saliva Collected in Field Studies (2000) (74)
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial (2018) (74)
Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation (2007) (74)
Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study) (2011) (74)
A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. (1995) (73)
Comparative Efficacy of Famciclovir and Valacyclovir for Suppression of Recurrent Genital Herpes and Viral Shedding (2006) (73)
Safety profile of recombinant canarypox HIV vaccines. (2004) (73)
Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. (2009) (73)
Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59 (1996) (73)
Genital herpes complicating pregnancy. (1998) (73)
Clinical correlates of herpes simplex virus viremia among hospitalized adults. (2009) (71)
In vitro sensitivity to acyclovir in genital herpes simplex viruses from acyclovir-treated patients. (1983) (71)
HIV-1 Vaccines and Adaptive Trial Designs (2011) (71)
Frequency of Asymptomatic Shedding of Herpes Simplex Virus in Women With Genital Herpes (1990) (71)
Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System (2008) (70)
Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. (1995) (70)
Human immunodeficiency virus vaccine trials. (2012) (69)
Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. (2001) (69)
Allogeneic marrow transplantation in patients positive for hepatitis B surface antigen. (1991) (69)
Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. (2005) (69)
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. (1996) (69)
Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study (2011) (68)
Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. (2004) (68)
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. (1994) (68)
High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. (2005) (67)
A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection (2000) (67)
Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. (1982) (67)
Detection of hepatitis C virus RNA: comparison of one-stage polymerase chain reaction (PCR) with nested-set PCR (1993) (67)
Approaches to preventative and therapeutic HIV vaccines. (2016) (67)
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children (2010) (67)
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. (2019) (66)
Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. (2004) (66)
The need for a global HIV vaccine enterprise. Policy forum. (2003) (65)
Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. (1986) (65)
Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA (2005) (65)
Human herpesvirus 6 DNA in blood cells of human immunodeficiency virus-infected men: correlation of high levels with high CD4 cell counts. (1994) (65)
Dynamics of hepatitis C virus replication in human liver. (2003) (65)
Viral Hepatitis Among Young Men Who Have Sex With Men: Prevalence of Infection, Risk Behaviors, and Vaccination (2003) (65)
Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. (2002) (64)
Combination prevention for COVID-19 (2020) (64)
Treatment of herpes simplex virus infections. (1987) (64)
Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. (1984) (63)
Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor (2003) (63)
New concepts in understanding genital herpes (2009) (63)
Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 8 DNA in Semen (1999) (62)
Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. (2004) (62)
Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. (2000) (62)
Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract (2013) (62)
How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis? (2003) (62)
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. (2004) (61)
HIV Infection and Human Herpesvirus-8 Oral Shedding Among Men Who Have Sex with Men (2004) (61)
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. (2003) (61)
Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection (2014) (61)
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. (2016) (60)
Herpes Simplex Virus Type 2 and Risk of Intrapartum Human Immunodeficiency Virus Transmission (2007) (60)
Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. (1999) (60)
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. (2004) (60)
Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. (2011) (60)
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. (2004) (60)
Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. (2009) (59)
Detailed Characterization of T Cell Responses to Herpes Simplex Virus-2 in Immune Seronegative Persons (2010) (59)
Protein-specific cervical antibody responses to primary genital herpes simplex virus type 2 infections. (1994) (59)
Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults (2016) (59)
Interpreting HIV Serodiagnostic Test Results in the 1990s: Social Risks of HIV Vaccine Studies in Uninfected Volunteers (1994) (58)
Identification of multiple strains of cytomegalovirus in homosexual men. (1989) (58)
Oral shedding of herpes simplex virus type 2 (2004) (58)
Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. (1984) (57)
Risk factors for herpes simplex virus transmission to pregnant women: a couples study. (2005) (57)
Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). (2008) (57)
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial (2017) (57)
The diagnosis and treatment of genital herpes. (1982) (57)
Antiviral chemotherapy: New directions for clinical application and research (1986) (57)
Post-step modifications for research on HIV vaccines. (2009) (57)
Challenges in genital herpes simplex virus management. (2002) (56)
Cytomegalovirus infection in women attending a sexually transmitted disease clinic. (1990) (56)
Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. (2011) (56)
Diversity in CD8+ T Cell Function and Epitope Breadth Among Persons with Genital Herpes (2010) (56)
Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2 (2009) (56)
Seroprevalence of herpes simplex virus infections in a family medicine clinic. (1995) (55)
HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men (2009) (55)
Cervical but not urinary excretion of cytomegalovirus is related to sexual activity and contraceptive practices in sexually active women. (1995) (55)
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. (2019) (55)
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. (2011) (54)
Disseminated neonatal herpes simplex virus type 1 from a maternal breast lesion. (1983) (54)
The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. (2011) (54)
Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma. (1997) (54)
Impact of HIV Infection and Kaposi Sarcoma on Human Herpesvirus-8 Mucosal Replication and Dissemination in Uganda (2009) (54)
HSV shedding. (2004) (53)
Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia (2017) (53)
Use of the MagNA Pure LC Automated Nucleic Acid Extraction System followed by Real-Time Reverse Transcription-PCR for Ultrasensitive Quantitation of Hepatitis C Virus RNA (2004) (52)
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. (1984) (52)
Herpes Simplex Inhibits the Capacity of Lymphoblastoid B Cell Lines to Stimulate CD4+ T Cells1 (2001) (52)
H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients (2011) (52)
Abacavir hypersensitivity reaction in primary HIV infection (2006) (52)
Risk factors for HIV-1 shedding in semen. (1999) (51)
Gender Differences in Clinical Presentation and Outcomes of Epidemic Kaposi Sarcoma in Uganda (2010) (51)
Immunoblot analysis of the humoral immune response in primary cytomegalovirus infection. (1988) (51)
Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. (2006) (51)
Diminished interferon-gamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. (1992) (51)
Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs (2011) (50)
Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. (2016) (50)
An Effector Phenotype of CD8+ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection (2012) (50)
Lower Genitourinary Tract Sources of Seminal HIV (2006) (50)
Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes (2007) (50)
Evaluation of Real-Time PCR versus PCR with Liquid-Phase Hybridization for Detection of Enterovirus RNA in Cerebrospinal Fluid (2003) (49)
Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. (1996) (49)
Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. (1994) (49)
Persistent fever in patients with neutropenia. (2002) (49)
Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays (2021) (49)
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. (2012) (49)
Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. (2006) (48)
Quantitation of hepatitis C viral RNA in sera of hemodialysis patients: gender-related differences in viral load. (1994) (48)
Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells (2017) (48)
Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. (1997) (48)
Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. (1999) (47)
Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa (2011) (47)
Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. (2000) (47)
Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth. (1992) (47)
Recurrent genital herpes among women: symptomatic v. asymptomatic viral shedding. (1978) (47)
Long Term Persistence of Herpes Simplex Virus-Specific CD8+ CTL in Persons with Frequently Recurring Genital Herpes1 (2000) (47)
HHV‐8 infection: a model for reactivation and transmission (2002) (47)
Ineffectiveness of topical ether for the treatment of genital herpes simplex virus infection. (1978) (47)
Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract (2016) (46)
Use of adenovirus type-5 vectored vaccines: a cautionary tale (2020) (46)
Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. (2015) (46)
A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections (1994) (46)
Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. (2013) (46)
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120 (2017) (45)
Infections with herpes simplex viruses (2). (1986) (45)
A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy. (1995) (45)
HSV-2 transmission. (2004) (45)
Herpes simplex virus (HSV)-specific proliferative and cytotoxic T-cell responses in humans immunized with an HSV type 2 glycoprotein subunit vaccine (1988) (44)
Early Induction and Maintenance of Env-Specific T-Helper Cells following Human Immunodeficiency Virus Type 1 Infection (2003) (44)
Epidemic infections caused by respiratory syncytial virus in institutionalized young adults. (1987) (43)
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir (2010) (43)
HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection (2012) (43)
Rapidly Cleared Episodes of Oral and Anogenital Herpes Simplex Virus Shedding in HIV-Infected Adults (2010) (43)
Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. (1984) (43)
Combination therapy with zidovudine, didanosine and saquinavir. (1996) (43)
Laboratory diagnosis of herpes simplex virus infections. Principles guiding the development of rapid diagnostic tests. (1986) (43)
Risk of Recurrence after Treatment of First‐episode Genital Herpes with Intravenous Acyclovir (1985) (43)
HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. (2011) (42)
HIV serodiscordant sex partners and the prevalence of human herpesvirus 8 infection among HIV negative men who have sex with men: baseline data from the EXPLORE Study (2006) (42)
Continued evolution of HIV‐1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV‐1 in monocytes and CD4+ T cells of patients with discontinued therapy (2006) (42)
Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine (1985) (42)
Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. (2008) (42)
Safety and efficacy assessment of the HVTN 503/Phambili Study: A double-blind randomized placebo-controlled test-of-concept study of a Clade B-based HIV-1 vaccine in South Africa (2011) (42)
Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. (2008) (42)
How Many Human Immunodeficiency Virus Type 1-Infected Target Cells Can a Cytotoxic T-Lymphocyte Kill? (2005) (41)
Prevalence and incidence of herpesvirus infections among homosexually active men. (1984) (41)
Secretory IgA antibody in cervicovaginal secretions from women with genital infection due to herpes simplex virus. (1984) (41)
Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. (2004) (41)
Rapid Viral Expansion and Short Drug Half-Life Explain the Incomplete Effectiveness of Current Herpes Simplex Virus 2-Directed Antiviral Agents (2013) (41)
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (1999) (41)
Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. (1999) (41)
Seminal shedding of human immunodeficiency virus type 1 and human cytomegalovirus: evidence for different immunologic controls. (1995) (41)
Independent and Cooperative Antiviral Actions of Beta Interferon and Gamma Interferon against Herpes Simplex Virus Replication in Primary Human Fibroblasts (2007) (41)
First-episode, recurrent, and asymptomatic herpes simplex infections. (1988) (41)
Provision of treatment in HIV-1 vaccine trials in developing countries (2003) (40)
HIV Vaccine Development: A Progress Report (1994) (40)
Adolescents Are More Likely to Develop Posttransplant Lymphoproliferative Disorder After Primary Epstein-Barr Virus Infection Than Younger Renal Transplant Recipients (2007) (40)
Neonatal Herpes Should be a Reportable Disease (2005) (40)
CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice (2020) (40)
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults (2017) (40)
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders (2015) (40)
Influenza Viral RNA Detection in Blood as a Marker to Predict Disease Severity in Hematopoietic Cell Transplant Recipients (2012) (40)
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens (2011) (40)
T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?1 (2003) (40)
Evidence for Limited Genetic Compartmentalization of HIV-1 between Lung and Blood (2009) (39)
HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1 (2013) (39)
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. (2000) (39)
Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. (1998) (39)
Inhibition of MHC Class I Is a Virulence Factor in Herpes Simplex Virus Infection of Mice (2005) (39)
Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation (2017) (39)
Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling (2007) (39)
Herpes simplex virus detection from genital lesions: a comparative study using antigen detection (HerpChek) and culture (1993) (38)
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa (2019) (38)
Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non‐myeloablative allogeneic stem cell transplantation (2003) (38)
An Important Role for Major Histocompatibility Complex Class I-Restricted T Cells, and a Limited Role for Gamma Interferon, in Protection of Mice against Lethal Herpes Simplex Virus Infection (1999) (38)
γδ+ T Cells Involvement in Viral Immune Control of Chronic Human Herpesvirus 8 Infection1 (2008) (38)
Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1‐infected women (1999) (38)
Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. (1997) (37)
Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. (1998) (37)
Population Level Impact of an Imperfect Prophylactic Vaccine for Herpes Simplex Virus-2 (2010) (37)
Detection of rectal antibodies to HIV-1 by a sensitive chemiluminescent western blot immunodetection method. (1994) (37)
The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation (2010) (37)
Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. (2007) (37)
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. (2000) (37)
Introduction of a novel parechovirus RT-PCR clinical test in a regional medical center. (2011) (37)
Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination (1996) (36)
Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus (1988) (36)
Acquisition of neonatal HSV-1 infection from a paternal source contact. (1983) (36)
Evaluation of a quantitative competitive PCR assay for measuring herpes simplex virus DNA content in genital tract secretions (1997) (36)
Use of predictive markers of HIV disease progression in vaccine trials. (2009) (35)
Oral acyclovir for treatment of first-episode herpes simplex virus proctitis. (1988) (35)
Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. (2003) (35)
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. (2005) (35)
WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplant Recipients (2012) (35)
Treatment of Recurrent Genital Herpes Simplex Infections with Oral Acyclovir. A Controlled Trial (1984) (35)
The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. (1994) (35)
Serial in vivo passage of HIV-1 infection in Macaca nemestrina. (1997) (34)
Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection (1991) (34)
The complex challenges of HIV vaccine development require renewed and expanded global commitment (2019) (34)
Rapid Detection Directly from Patient Serum Samples of Human Cytomegalovirus UL97 Mutations Conferring Ganciclovir Resistance (2007) (34)
Intrapatient sequence variation of the gag gene of human immunodeficiency virus type 1 plasma virions (1996) (33)
Unintegrated HIV‐1 circular 2‐LTR proviral DNA as a marker of recently infected cells: Relative effect of recombinant CD4, zidovudine, and saquinavir in vitro (1999) (33)
MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load (2012) (33)
High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results (2020) (32)
HSV type specific antibody tests: patients are ready, are clinicians? (1997) (32)
In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques (2010) (32)
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men (2015) (32)
Transmission of herpes simplex virus from father to neonate. (1983) (32)
Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection. (1995) (32)
Detection of asymptomatic herpes simplex virus infections after vaccination (1987) (32)
Virus-specific antibodies in sera from patients with genital herpes simplex virus infection (1982) (32)
Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina. (1995) (32)
Detection of herpes simplex virus DNA from genital lesions by in situ hybridization (1988) (32)
Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. (1998) (31)
Transmission of genital herpes by donor insemination. (1989) (31)
Transmission of Genital Herpes in Couples With One Symptomatic and One Asymptomatic Partner: A Prospective Study (1989) (31)
High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection. (2006) (31)
Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus‐8 replication in HIV‐1 seropositive men (2011) (30)
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes (2016) (30)
Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. (2015) (30)
Underestimation of HSV‐2 Seroprevalence in a High‐risk Population by Microneutralization Assay (1993) (30)
Raising the Consciousness for Identifying and Controlling Viral STDs: Fears and Frustrations Thomas Parran Award Lecture (1998) (30)
Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. (2010) (30)
Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. (2004) (30)
Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. (2001) (29)
Ineffectiveness of topical idoxuridine in dimethyl sulfoxide for therapy for genital herpes. (1982) (29)
Assessment of a Combined Testing Strategy for Detection of Antibodies to Human Herpesvirus 8 (HHV-8) in Persons with Kaposi's Sarcoma, Persons with Asymptomatic HHV-8 Infection, and Persons at Low Risk for HHV-8 Infection (2002) (29)
Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses. (2008) (29)
Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. (2005) (29)
Rapid Polymerase Chain Reaction Assay to Detect Herpes Simplex Virus in the Genital Tract of Women in Labor (2010) (29)
Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. (2010) (29)
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (1998) (28)
A double-blind, placebo-controlled trial of the effect of chronically administered oral acyclovir on sperm production in men with frequently recurrent genital herpes. (1988) (28)
Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfected women. (2001) (28)
Tissue-resident T cell derived cytokines eliminate herpes simplex virus-2 infected cells. (2020) (28)
Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. (2009) (28)
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA (2017) (28)
Changes in the Soluble Mucosal Immune Environment During Genital Herpes Outbreaks (2012) (28)
Valganciclovir for the Suppression of Epstein-Barr Virus Replication (2017) (28)
138 – Herpes Simplex Virus (2015) (28)
Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates. (1984) (28)
Broadly Neutralizing Antibodies for HIV Prevention. (2020) (28)
Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case–control study (2011) (27)
Risk of Recurrence after First Episode of Genital Herpes: Relation to HSV Type and Antibody Response (1982) (27)
A Randomized, Double-Blind, Placebo-Controlled Trial of Systemically Administered Interferon-α, -β, or -γ in Combination with Cryotherapy for the Treatment of Condyloma Acuminatum (1995) (27)
Cervical antibodies in patients with oral herpes simplex virus type 1 (HSV-1) infection: local anamnestic responses after genital HSV-2 infection (1994) (27)
CTL in Persons with Frequently Recurring Genital Herpes (2000) (27)
Self-Collection of Foam Nasal Swabs for Respiratory Virus Detection by PCR among Immunocompetent Subjects and Hematopoietic Cell Transplant Recipients (2012) (26)
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial (2019) (26)
Inhibition of apoptosis by primary isolates of herpes simplex virus (2001) (26)
A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group. (1998) (26)
Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms (2005) (26)
Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus. (1995) (26)
Primary human herpesvirus‐6 associated with an afebrile seizure in a 3‐week‐old infant (2002) (26)
Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. (2011) (26)
An update on short-course intermittent and prevention therapies for herpes labialis. (2007) (26)
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020) (25)
Progression of human immunodeficiency virus type-1 infection after allogeneic marrow transplantation. (1990) (25)
Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial (2022) (25)
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. (2010) (25)
Herpes simplex viral pneumonitis in childhood. (1984) (25)
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study (2022) (25)
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap (2016) (25)
Persistence of mucosal T cell responses to herpes simplex virus type 2 (HSV-2) in the female genital tract (2014) (25)
Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes. (1990) (25)
Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials (2015) (25)
Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. (2014) (24)
Penile intraepithelial neoplasia: clinical presentation and an analysis of the physical state of human papillomavirus DNA. (1993) (24)
Frequent Genital HSV-2 Shedding among Women during Labor in Soweto, South Africa (2014) (24)
Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trials (2020) (24)
Acquired immunodeficiency syndrome. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. (1991) (24)
Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue. (2015) (24)
Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. (2018) (24)
Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination (2012) (24)
Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. (1998) (24)
HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. (2007) (24)
Endemic spread of herpes simplex virus type 1 among adolescent wrestlers and their coaches. (1999) (24)
Immunostimulation by induced expression of NKG2D and its MIC ligands in HTLV-1-associated neurologic disease (2006) (24)
Robust antibody and cellular responses induced by DNA-only vaccination for HIV. (2020) (23)
Perspectives on switching oral acyclovir from prescription to over-the-counter status: report of a consensus panel. (1998) (23)
Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (23)
HIV vaccines: mosaic approach to virus diversity (2010) (23)
Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants (2018) (22)
Herpes simplex virus infections during the decade since the licensure of acyclovir (1993) (22)
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines (2020) (22)
Transmission of genital herpes by donor insemination (1990) (22)
Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants. (2016) (22)
IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. (2011) (22)
A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens (2015) (22)
Human herpesvirus 6 DNA in peripheral blood cells and saliva from immunocompetent individuals (1994) (22)
Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals (2018) (22)
Evaluation of new anti-infective drugs for the treatment of syphilis. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (21)
Safety and pharmacokinetics of aciclovir in women following release from a silicone elastomer vaginal ring. (2012) (21)
Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. (1997) (21)
Acyclovir Achieves a Lower Concentration in African HIV-Seronegative, Herpes Simplex Virus 2-Seropositive Women than in Non-African Populations (2012) (21)
Isolation and characterization of six new genome types of human adenovirus types 1 and 2 (1985) (21)
Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. (2010) (21)
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. (1996) (21)
Calibration curves for real-time PCR. (2005) (21)
Primary and recurrent concomitant genital infection with herpes simplex virus types 1 and 2. (1983) (21)
Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy (2017) (20)
Sequence-Based Methods for Identifying Epidemiologically Linked Herpes Simplex Virus Type 2 Strains (2006) (20)
Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines". (2014) (20)
Human herpesvirus 6 infection in febrile infants ninety days of age and younger (2002) (20)
Differential effect of systemic acyclovir treatment of genital HSV‐2 infections on antibody responses to individual HSV‐2 proteins (1988) (20)
Alteration of lymphocyte transformation response to herpes simplex virus infection by acyclovir therapy (1984) (20)
Quantitation of human immunodeficiency virus in the blood. (1990) (20)
Herpes Simplex Virus Inhibits Apoptosis through the Action of Two Genes , Us 5 and Us 3 (1999) (20)
The danger within. (2004) (20)
Prevention of herpes simplex virus type 2 transmission with antiviral therapy. (2004) (20)
Introduction: Is viral shedding a surrogate marker for transmission of genital herpes? (2004) (20)
Human herpesvirus 8 infection among adolescents in the REACH cohort. (2006) (20)
Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. (1988) (20)
Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. (1994) (19)
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells (2019) (19)
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. (2011) (19)
An update on short-course episodic and prevention therapies for herpes genitalis. (2007) (19)
HIV infection in vaccinated volunteers. (1994) (19)
Modeling Plasma Virus Concentration and CD4+ T Cell Kinetics during Primary HIV Infection (1999) (19)
Longitudinal analysis of herpes simplex virus-specific CD4+ cell clonotypes in infected tissues and blood. (2005) (19)
Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa (2016) (19)
Comparison of Neutralization and DNA Restriction Enzyme Methods for Typing Clinical Isolates of Human Adenovirus (1985) (18)
Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. (2006) (18)
Herpes simplex type 2 infection in the developing world: is it time to address this disease? (2000) (18)
Concordance Between HIV Source Partner Identification and Molecular Confirmation in Acute Retroviral Syndrome (2002) (18)
High-Dose Valacyclovir Decreases Plasma HIV-1 RNA More Than Standard-Dose Acyclovir in Persons Coinfected with HIV-1 and HSV-2: A Randomized Crossover Trial (2013) (18)
Fomites and herpes simplex viruses: a case for nonvenereal transmission? (1983) (18)
Comparison of intramuscular recombinant alpha interferon (rIFN-2A) with topical acyclovir for the treatment of first-episode herpes genitalis and prevention of recurrences (1989) (18)
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. (2000) (18)
Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care. (2009) (18)
A prospective study of hormonal contraceptive use and cervical shedding of herpes simplex virus in human immunodeficiency virus type 1-seropositive women. (2002) (18)
Poor Correlation Between Genital Lesions and Detection of Herpes Simplex Virus in Women in Labor (2005) (18)
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants (2016) (17)
Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children (2017) (17)
A selective defect in tissue factor mRNA expression in monocytes from AIDS patients. (1990) (17)
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy (2016) (17)
Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney (2000) (17)
Adverse effects with acyclovir and meperidine. (1985) (17)
Fatal Human Metapneumovirus Infection in Stem Cell Transplant Recipients. (2004) (17)
Correlates of Human Herpesvirus-8 Seropositivity Among U.S. Military Members Recently Infected With Human Immunodeficiency Virus (2003) (17)
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial (2022) (17)
Membranoproliferative glomerulonephritis associated with hepatitis C virus infection (1993) (17)
Uptake of male circumcision in an HIV vaccine efficacy trial. (2009) (17)
Corrigendum: Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection (2013) (17)
Joel David Meyers, M.D., Tribute (1992) (16)
Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. (2002) (16)
Erratum: Clinical and epidemiologic features of primary HIV infection (Annals of Internal Medicine (1996) 125 (257-264)) (1997) (16)
Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. (1992) (16)
Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts (2020) (16)
A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group). (1992) (16)
A reduced dose of zidovudine in patients with AIDS. (1991) (16)
Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study (2008) (16)
Do scarce targets or T killers control primary HIV infection? (2002) (16)
Successful Isolation of Infectious and High Titer Human Monocyte-Derived HIV-1 from Two Subjects with Discontinued Therapy (2013) (16)
A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection (2018) (16)
Frequent Detection of Human Adenovirus from the Lower Gastrointestinal Tract in Men Who Have Sex with Men (2010) (16)
Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor (2011) (16)
High Asymptomatic Carriage With the Omicron Variant in South Africa (2022) (16)
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans (2020) (15)
Preventing acquisition of HIV is the only path to an AIDS-free generation (2017) (15)
Risk of Recurrence after First Episodes of Genital Herpes. Relation to HSV Type and Antibody Response (1982) (15)
Reducing T cell activation as a therapy for human immunodeficiency virus infection. (1995) (15)
Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights (2021) (15)
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women (2017) (15)
Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir (1993) (15)
Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. (2000) (15)
HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. (2012) (15)
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings (2021) (14)
Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins. (1988) (14)
Cytomegalovirus viral load kinetics as surrogate endpoints after allogeneic transplantation. (2020) (14)
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein (2020) (14)
Double-Blind Controlled Trial of Topical Acyclovir in Genital Herpes Simplex Virus Infections (1983) (14)
Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. (2011) (14)
Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance. (2007) (14)
A randomized, double-blind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum. (1997) (14)
Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons (2016) (14)
Persistent hepatitis C virus infection after liver transplantation (1995) (14)
Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials (2020) (14)
Live, attenuated influenza A/England/42/72 (H3N2) virus vaccine: a field trial. (1976) (14)
Case report: primary human herpesvirus-6 associated with an afebrile seizure in a 3-week-old infant. (2002) (14)
An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2 (2020) (14)
In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. (2016) (14)
Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. (2016) (14)
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. (2016) (14)
Potential for combined therapy with 348u87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir‐resistant herpes simplex virus infection (1993) (13)
Stigma, Implicit Bias, and Long-Lasting Prevention Interventions to End the Domestic HIV/AIDS Epidemic. (2020) (13)
Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation. (2019) (13)
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models (2015) (13)
Effect of isoprinosine on the cellular immune response in initial genital herpes virus infection (1979) (13)
Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials (2020) (13)
Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. (1998) (13)
Type specificity of complement-fixing antibody against herpes simplex virus type 2 AG-4 early antigen in patients with asymptomatic infection (1986) (13)
CMV viral load kinetics as surrogate endpoints after allogeneic transplantation (2021) (13)
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? (2016) (13)
Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial (2022) (13)
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial (2022) (13)
Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. (1996) (13)
Infection of Macaca nemestrina brain with human immunodeficiency virus type 1. (1995) (12)
Herpes simplex virus-associated sepsis in a previously infected immunocompetent adult. (2003) (12)
Genital human papillomavirus infections (1987) (12)
Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control group (2012) (12)
Subclinical shedding of HSV: its potential for reduction by antiviral therapy. (1996) (12)
Broadly neutralizing antibodies to prevent HIV-1 (2017) (12)
A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. (2016) (12)
Treatment of HIV infection--progress in perspective. (1992) (12)
Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study (2021) (12)
A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy. (2012) (12)
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens (2020) (12)
Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial (2019) (11)
Genital herpes simplex virus infections (1984) (11)
Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. (2004) (11)
Preinfection Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T Lymphocytes Failed To Prevent HIV Type 1 Infection from Strains Genetically Unrelated to Viruses in Long-Term Exposed Partners (2009) (11)
Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques (2018) (11)
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation (2021) (11)
OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial (2009) (11)
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody (2021) (11)
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated (2021) (11)
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation (2021) (11)
The natural history of HIV infection: implications for the assessment of antiretroviral therapy. (1993) (10)
Comparison of assays to detect cytomegalovirus shedding in the semen of HIV-infected men. (2000) (10)
Evaluating the Efficacy of COVID-19 Vaccines (2020) (10)
Comparison of monoclonal antibodies for rapid detection of cytomegalovirus in spin-amplified plate cultures (1989) (10)
Quantitation of Hepatitis C Virus RNA (1996) (10)
Polymerase chain reaction diagnosis of primary human herpesvirus-6 infection in the acute care setting. (2006) (10)
Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy? (2017) (10)
Daily Acyclovir Delays HIV-1 Disease Progression Among HIV-1/HSV-2 Dually-Infected Persons: A Randomized Trial (2010) (10)
Lack of toxicity in two cases of neonatal acyclovir overdose (1989) (10)
HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients. (1994) (10)
CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression. (2006) (10)
B cells, antibody-secreting cells and virus-specific antibodies respond to herpes simplex virus-2 reactivation in skin. (2021) (10)
The Natural History of Genital Herpes Simplex Virus (1985) (10)
Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial (2022) (10)
Automated microneutralization: method and comparison with western blot for type-specific detection of herpes simplex antibodies in two pregnant populations. (1995) (10)
Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons (2018) (9)
Antiviral Chemotherapy 4 (1996) (9)
75: Prevention of Late CMV Disease After HCT: A Randomized Double-Blind Multicenter Trial of Valganciclovir (VGCV) Prophylaxis Versus PCR-guided GCV/VGCV Preemptive Therapy (2008) (9)
Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines (2020) (9)
Routine typing of herpes simplex virus isolates. (1985) (9)
Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes (2021) (9)
Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily * (2004) (9)
Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation (2000) (9)
Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants. (2009) (9)
Chlamydia pneumoniae respiratory infection after allogeneic stem cell transplantation. (2002) (9)
Comparison of neutralization and DNA restriction enzyme methods for typing clinical isolates of human adenovirus (1985) (9)
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials (2021) (9)
Distinct populations of antigen-specific tissue-resident CD8+ T cells in human cervix mucosa (2021) (9)
Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. (2011) (9)
Evaluation of new anti-infective drugs for the treatment of vaginal infections. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (9)
Antiviral therapies for long-term suppression of genital herpes. (1999) (9)
Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants (2014) (9)
Potential Benefits of a Serodiagnostic Test for Herpes Simplex Virus Type 1 (HSV-1) to Prevent Neonatal HSV-1 Infection (2002) (9)
Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics. (2022) (8)
Safety and Efficacy of zidovudine in asymptomatic HIV infected individuals withless than 500 CD4+ cells/mm3. (1990) (8)
HSV-2 and HIV: consequences of an endemic opportunistic infection. (1997) (8)
Towards prediction of degenerate CTL epitope recognition (2008) (8)
Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa (2021) (8)
A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes. (1991) (8)
Genital herpes simplex virus infections in adults. (1984) (8)
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. (1993) (8)
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition (2022) (8)
Therapy of cytomegalovirus infections with ganciclovir: a critical appraisal. (1992) (7)
Neonatal herpes simplex virus infection: relapse after initial therapy and transmission from a mother with an asymptomatic genital herpes infection and erythema multiforme. (1987) (7)
Broadly neutralizing monoclonal antibodies for HIV prevention (2021) (7)
The Acceptance of HSV-Testing Partners of HSV-2 Seronegative Pregnant Women (2009) (7)
Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition (2017) (7)
Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021 (2020) (7)
Neonatal herpes simplex virus infection in King County, Washington. Increasing incidence and epidemiologic correlates (1984) (7)
Human T lymphocyte cooperation in proliferative responses to specific antigens, mitogens, and alloantigens. (1981) (7)
Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months (2022) (7)
Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads (2021) (6)
Current Concepts Maternal and Neonatal Herpes Simplex Virus Infections (2009) (6)
A randomized, double-blind, placebo-controlled trial of systemically administered interferon-alpha, -beta, or -gamma in combination with cryotherapy for the treatment of condyloma acuminatum. (1995) (6)
Lessons from HIV and hepatitis viruses. (2004) (6)
Analysis of a major target of the human immune response to cytomegalovirus using monoclonal antibodies (1988) (6)
Genital HIV-1 RNA Quantity Predicts Risk of Heterosexual HIV-1 Transmission (2011) (6)
Isolation of Herpes Simplex Virus From the Genital Tract During Symptomatic Recurrence on the Buttocks (2006) (6)
Clinical studies with herpes simplex virus type 2 Curtis strain vaccine. (1991) (6)
Evaluation of new anti-infective drugs for the treatment of genital infections due to herpes simplex virus. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (6)
Clinical and Virologic Response to Episodic Acyclovir for Genital Ulcers Among HIV-1 Seronegative, Herpes Simplex Virus Type 2 Seropositive African Women: A Randomized, Placebo-Controlled Trial (2012) (6)
34 Influenza infections after stem cell transplantation (SCT): Risk factors, mortality and the effect of antiviral therapy (2003) (6)
Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. (2009) (6)
Nuclear factor kappa B is required for the production of infectious human herpesvirus 8 virions (2014) (6)
The natural history of HIV infection (1993) (6)
Appendix Population level impact of an imperfect prophylactic HSV-2 vaccine (2009) (5)
P1-S5.25 Acyclovir and transmission of HSV-2 from HSV-2/HIV-1 dually infected persons (2011) (5)
The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. (2009) (5)
Increasing prevalence of HSV-2 points to need for more effective prevention strategies. (2002) (5)
Kinetics of the humoral immune response measured by antibody-dependent cell-mediated cytotoxicity and neutralization assays in genital herpesvirus infections. (1989) (5)
From the Infectious Diseases Society of America. Countering the epidemic of sexually transmitted diseases: a call to action. (1982) (5)
Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. (2011) (5)
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission (2021) (5)
Evaluation of new anti-infective drugs for the treatment of chancroid. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (5)
Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. (2006) (5)
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults (2020) (5)
Cesarean delivery in women with genital herpes in washington state, 1989-1991. (1997) (5)
The path to find an HIV vaccine (2021) (5)
KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine (2022) (5)
The Safety and Efficacy of High-Dose (HD) Acyclovir (ACV) in Neonatal Herpes Simplex Virus (HSV) Infections (1999) (4)
A siege of hepatitis: Fighting a defiant virus (2011) (4)
Chronic Fatigue Syndrome-Reply (1991) (4)
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants (2021) (4)
Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
Genital herpes simplex virus infection (1977) (4)
Cotton-wool spots in primary HIV infection. (1998) (4)
Detection of Adeno-Associated Virus Viremia in Hematopoietic Cell Transplant Recipients (2011) (4)
Characterization of lytic human herpesvirus-8 gene expression in Kaposi sarcoma tumor tissue and its clinical correlates (2010) (4)
Random-Reaction-Seed Method for Automated Identification of Neurite Elongation and Branching (2019) (4)
Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques (2021) (4)
NIH conference. HIV vaccine development: a progress report. (1994) (4)
How good is HIV envelope glycoprotein vaccine as a T-lymphocyte stimulant? (1991) (3)
AIDS : problems and prospects (1993) (3)
Confirming Shedding of Human Herpesvirus 8 in Urine from Infected Patients in Brazil (2005) (3)
Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome (1998) (3)
Evaluation of new anti-infective drugs for the treatment of sexually transmitted chlamydial infections and related clinical syndromes. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (3)
simplex virus types 1 and 2 in human sera. assay for detecting antibodies to herpes glycoprotein G-specific immunodot enzyme Comparison of Western blot (immunoblot) and (2013) (3)
Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals. (1994) (3)
CMV Viral Load Kinetics as Surrogate Endpoints for Antiviral Prophylaxis Trials (2020) (3)
Plasma viremia and recovery of HIV from semen (1992) (3)
Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. (2011) (3)
Acyclovir Suppresses Subclinical Shedding of Herpes Simplex Virus (1996) (3)
Simplex Virus DNA in Clinical Samples Quantitative Assay for Detecting Herpes Development of a High-Throughput (1999) (3)
Specific humoral immunity in patients receiving acyclovir treatment for primary genital herpes simplex virus (HSV) infections (1982) (3)
Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. (2022) (3)
Donor-recipient match at the HLA-DQB locus is associated with recurrence of chronic hepatitis following liver transplantation for end stage hepatitis C (1994) (3)
TOPICAL SURFACTANT THERAPY FOR RECURRENT HERPES SIMPLEX INFECTION (1986) (3)
Human herpes virus eight in prostate tissue of men with Kaposi's sarcoma (1997) (3)
O3-S5.03 High-dose valacyclovir decreases plasma HIV-1 levels more than standard dose acyclovir in HIV-1, HSV-2 positive persons: a randomised, crossover trial (2011) (3)
Kaposi’s Sarcoma—Associated Human Herpes Virus Eight: Localization of Viral Gene Expression and Viral Latency (2000) (3)
In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cells—A Tool to Interrogate a Functional Immune Response Ex Vivo (2016) (3)
Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant (2018) (3)
Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir. (2022) (3)
Incidence of genital ulcers and HSV+ genital ulcers in trial of HSV-2 suppression to prevent HIV acquisition (HPTn 039) (2008) (3)
IgG subclass of anti-HSV antibodies following neonatal HSV infections (1986) (3)
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA (2023) (3)
A placebo-controlled trial of topical 8% arildone cream early in recurrent genital herpes (1986) (3)
Reevaluating HIV vaccine clinical trials policy for infants. (2015) (2)
Behind the Scenes Heroes: The COVID-19 Vaccine Data and Safety Monitoring Board (2021) (2)
HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens (2022) (2)
LBO-1.1 Acyclovir achieves lower concentration in African HIV−, HSV-2+ women compared to non-African populations, possibly explaining lower herpes suppression (2011) (2)
O4-S1.04 Rapid spread of herpes simplex virus-2 in the human genital tract (2011) (2)
Presentation of neonatal herpes simplex virus infections (1986) (2)
For the Sake of God: a Reply to Jung (1990) (2)
AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy (2009) (2)
Genital Herpes Simplex Virus Infection: An Overview (1977) (2)
Antiretroviral therapy in primary HIV. (1999) (2)
Antiviral Chemotherapy 5 (1999) (2)
Innovative vaccine approaches—a Keystone Symposia report (2022) (2)
Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. (2019) (2)
Herpes Simplex Virus Pneumonia (2020) (2)
Recommendations for short-course therapies in herpes genitalis and herpes labialis. (2007) (2)
P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial (2009) (2)
Cell-mediated immunity in human herpesvirus infection: analysis by monoclonal antibodies. (1985) (2)
O3-S5.02 Frequent breakthrough genital HSV-2 shedding on standard and high dose valacyclovir (2011) (2)
Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017 (2020) (2)
Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. (2020) (2)
Increased oral Epstein-Barr virus shedding with HIV-1 co-infection is due to a combination of B cell activation and impaired cellular immune control (2019) (2)
The aspirational necessity of HIV prevention (2019) (2)
Real-time killing assays to assess the potency of a new anti-SIV CAR. (2020) (2)
The association of α4β7 expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies (2020) (2)
H 275 Y Mutant Pandemic ( H 1 N 1 ) 2009 Virus in Immunocompromised Patients (2019) (2)
Salivary shedding of HCV is associated with serum HCV RNA level and the presence of periodontal disease (2003) (2)
Herpes Simplex Virus Shedding: Biomarker for Disease Severity and Response to Antivirals (2015) (2)
OA01-06 LB. HIV-1 plasma RNA and risk of HIV-1 transmission (2009) (2)
Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell (2020) (2)
Cervical Antibodies to Herpes Simplex Virus Proteins in Pregnancy and Puerperium: A Pilot Study (1996) (2)
Diagnosis of genital herpes simplex virus infections. (1985) (2)
DNA viral load in plasma : evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients (2005) (2)
CD101 genetic variants modify regulatory and conventional T cell phenotypes and functions (2021) (2)
Herpes Simplex Virus Infection of Human Fibroblasts and Keratinocytes Inhibits Recognition by Cloned CD 8 + Cytotoxic T Lymphocytes (2013) (2)
One shot forward for HIV prevention (2014) (2)
Detection of hepatitis C virus RNA in normal cervical smears. (2003) (2)
56 Changing patterns in the risk for Cytomegalovirus infection and disease and treatment-related outcomes in the Era of preemptive antiviral therapy (2006) (1)
LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19) (2021) (1)
Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43 (2021) (1)
The status of cytomegalovirus vaccine. Discussion (1991) (1)
Topical acyclovir for genital herpes. (1982) (1)
Prevalence and determinants of seronegattvity to varicella zoster virus (VZV) in pregnant women (1997) (1)
Infection Of : A New Primate Model For Hiv-1 Infectionmacaca nemestrina: A New Primate Model For Hiv-1 Infection By Human Immunodeficiency Virus Type 1: A New Primate Model For Hiv-1 Infection (1993) (1)
Elimination of HSV-2 infected cells is mediated predominantly by paracrine effects of tissue-resident T cell derived cytokines (2019) (1)
Interrogation of HHV-8 transcriptome in KS tumors and association with KS presentation and outcomes in Uganda (2015) (1)
cystitis in allogeneic hematopoietic cell transplant recipients BK DNA viral load in plasma: evidence for an association with hemorrhagic (2013) (1)
Outcome of Hematopoietic Cell Transplantation (HCT) in Patients with Invasive Fungal Infection before HCT Without Regression or Stabilization of Radiographic Signs (2018) (1)
Varicella Zoster Virus CNS Disease in Hematopoietic Cell Transplantation: A Single Center Experience (2008) (1)
A CAR RNA FISH assay reveals functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue (2020) (1)
Do herpes simplex virus cultures of the newborn predict neonatal herpes (1996) (1)
Letter to the editor: human herpesvirus 6 serologic responses. (2001) (1)
Evaluation of the CHIRON®RIBA™HSV type -1/type-2 strip immunoblot assay (SIA) for typing of HSV antibodies (Ab) (1997) (1)
Immunobiology of herpes simplex virus (HSV) infections. (2001) (1)
Correction: Use of "biokitHSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA (2007) (1)
Reply to Richie and Villasante. (2013) (1)
Strategies for interrupting the transmission of genital and neonatal HSV infection (2004) (1)
RRScell method for automated learning immune cell phenotypes with immunofluorescence cancer tissue (2020) (1)
The human HIV vaccine pipeline: an update (2008) (1)
Special issues in clinical trials of new anti-infective drugs for the treatment of sexually transmitted diseases. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (1)
The challenges of an HIV vaccine enterprise - Response (2004) (1)
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine (2022) (1)
Novel engineered chimeric engulfment receptors trigger T cell effector functions against SIV-infected CD4+ T cells (2022) (1)
Update on HIV vaccines. (1997) (1)
Long term suppressive acyclovir (ACV) reduces VZV disease and ACV-resistant HSV after HCT (2006) (1)
HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
Cesarean Delivery in Women With Genital Herpes in Washington State, 1989–1991 (1997) (1)
Identifying predictors of increased quantities of human Herpesvirus 8 DNA detection at oropharyngeal and plasma sites among Ugandan adults with and without HIV and Kaposi Sarcoma (2012) (1)
Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination (2012) (1)
Identifying predictors of increased quantities of human Herpesvirus 8 DNA detection at oropharyngeal and plasma sites among Ugandan adults with and without HIV and Kaposi Sarcoma (2012) (1)
The seroepidemiology of Herpes simplex virus (HSV) among GUM clinic attenders at the Middlesex Hospita (1992) (1)
Interference of recombinant soluble CD4 immunoglobulin G in flow cytometric measurement of CD4+ lymphocytes. (1992) (1)
Application of Statistical Learning to Identify Omicron Mutations in SARS-CoV-2 Viral Genome Sequence Data From Populations in Africa and the United States (2022) (1)
Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19 (2022) (1)
Co-Administration of HIV Env Protein with DNA and/or NYVAC Vaccines in Humans Results in Earlier and Potent Generation of Anti-Env Antibody Responses (2019) (1)
Commentary: Lack of detection of HSV DNA in PBMCs and lymph nodes of HIV‐infected persons (1996) (1)
Accelerating clinical trial development in vaccinology: COVID-19 and beyond (2022) (1)
Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial (2012) (1)
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. (2023) (1)
Human Coronavirus (HCOV) and Rhinovirus (HRHV) Infection among Hematopoietic Stem Cell Transplantation (HCT) Recipients (2009) (1)
Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial (2023) (1)
Bridging the Gaps between Fundamental, Preclinical and Clinical Research: Report from a Global HIV Vaccine Enterprise Working Group (2010) (1)
Maternal genital herpes and gender of offspring. (1991) (1)
Use of placebos in Phase 1 preventive HIV vaccine clinical trials. (2015) (1)
Global Epidemiology of Genital Herpes and the Interaction of Herpes Simplex Virus with HIV (2004) (0)
Herpes Controlled: New Drugs, New Strategies, New Solutions (1998) (0)
1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals (2019) (0)
Infected Cutaneous Cells Immediate Early Proteins and Lysis of Lesions: Recognition of Viral Tegument and CD8 CTL from Genital Herpes Simplex (2001) (0)
Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia (2022) (0)
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation (2009) (0)
Infection ofMacacanemestrina byHuman Immunodeficiency Virus Type-1 (1992) (0)
Methodological issues in AIDS clinical trials. Discussion. Incorporation of trial results into clinical practice. (1990) (0)
Current Status of Antiviral Chemotherapy for Genital Herpes Simplex Virus Infection: Its Impact on Disease Control (1989) (0)
Recurrence Rates of Genital Herpes (1995) (0)
Cervical Antibodies to Herpes Simplex Virus Proteins in Pregnancy and Puerperium (1996) (0)
Generation of HIV-1–speciﬁc CD8 (cid:1) cell responses following allogeneic hematopoietic cell transplantation (2008) (0)
The seroepidemiology of Herpes simplex virus (HSV) in various populations in North London (1992) (0)
Immunologically relevant antigens from herpes simplex virus (2000) (0)
Human Bocavirus Transmission and Illness Among Pregnant Mothers and Infants in Ugandan Households (2017) (0)
Role of antibody-dependent cellular cytoxicity in neonatal infection with herpes simplex virus. Discussion (1991) (0)
Correction: Effects of Acyclovir and Meperidine (1986) (0)
TCR immune profiling reveals intrinsic clonal selection of tissue resident memory T cells in genital mucosa during human HSV-2 infection (2016) (0)
Development of Multiplexed Real-Time Quantitative PCR Assay for Detecting Human Adenoviruses (2008) (0)
Comparison ofIntramuscular Recombinant AlphaInterferon (rIFN-2A) withTopical Acyclovir fortheTreatment ofFirst- Episode Herpes Genitalis andPrevention ofRecurrences (1989) (0)
Serum Concentration of Antigen-Specific IgG Can Bias Interpretation of the Readout of Antibody-Dependent Phagocytosis Assay (2022) (0)
I133 The role of male circumcision in HIV prevention research (2009) (0)
Integrative proteomics and genomics supports a role for interferon gamma in the pathogenesis of Kaposi sarcoma and finds multiple candidate diagnostic proteins for early detection or prevention (2010) (0)
430 OSELTAMIVIR PROPHYLAXIIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS: A CASE-CONTROL STUDY. (2007) (0)
Cervical antibodies to herpes simplex virus during the chird trimester of pregnancy (1996) (0)
Discussion: What are the optimal regimens for postexposure chemoprophylaxis? (1997) (0)
Generating therapeutic/protective T-cell responses to tumors and HIV: "More is better, but will it be enough?" (2008) (0)
Hematopoietic Cell Transplant Recipients Immunocompetent Subjects and Respiratory Virus Detection by PCR among Self-Collection of Foam Nasal Swabs for (2012) (0)
Respiratory virus infection among hematopoietic cell transplantation (HCT) recipients: Quantitative viral load in symptomatic and asymptomatic infections (2006) (0)
Infection against Lethal Herpes Simplex Virus Gamma Interferon , in Protection of Mice I-Restricted T Cells , and a Limited Role for Histocompatibility Complex Class An Important Role for Major (1999) (0)
B cells and HSV-specific antibodies respond to HSV-2 reactivation in skin (2020) (0)
In memoriam: Walter E. Stamm. (2010) (0)
T cell therapy of CMV and HIV infection (1998) (0)
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials (2021) (0)
Monoclonal Antibodies for Diagnosis of Infectious Diseases in Humans (2019) (0)
Cytolytic Potentials of CD8+ T Cells Persisting in Genital Skin and Mucosa after HSV-2 Reactivation (45.16) (2009) (0)
THE EFFECT OF IMATINIB ON CMV REACTIVATION IN HEMATOPOIETIC CELL TRANSPLANTATION (2009) (0)
HIV-speciﬁc CD8 (cid:1) T cells from HIV (cid:1) individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo (2011) (0)
Ambulatory management of bacteremia and fever in bone marrow transplant patients (1999) (0)
Unrecognized versus asymptomatic HSV infection in HIV+ men (1996) (0)
IL-17c promotes peripheral nerve growth during human herpes simplex virus type 2 (HSV-2) infection (2017) (0)
207 Enhanced antigen capture, antigen-presenting cell (APC)-like function, and cytotoxic responses with chimeric engulfment receptor (CER) T cells (2021) (0)
E-104 Can non neutralizing antibodies be the basis for an effective HIV vaccine? Can we determine if RV 144 is “real or Memorex”? (2016) (0)
Daily valacyclovir treatment prevented the transmission of genital herpes in HSV-2 discordant couples (2004) (0)
Neonatal Herpes Simplex Virus Infection in King County, Washington (2017) (0)
Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial (2023) (0)
Open clinical trial of a prostaglandin inhibitor for frequent recurrences of genital herpes (1980) (0)
Memberanopoliferative Glomeulonephitis Associated with Hepatitis C Vius Infection (1993) (0)
CHRONIC FATIGUE SYNDROME. AUTHOR'S REPLY (1991) (0)
A Tribute to Stephen E. Straus, M.D. (1946–2007) (2007) (0)
Abstracts From the Infectious Diseases Society for Obstetrics and Gynecology (1996) (0)
A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection (1984) (0)
Recurring Genital Herpes CTL in Persons with + Virus-Specific CD 8 Long Term Persistence of Herpes Simplex (2000) (0)
CMV Infection and Disease after Nonmyeloablative (NM) HCT Revisited: Incidence, Risk Factors, Ganciclovir-Related Neutropenia and Outcome. (2005) (0)
Tissue resident memory CD8 T cells augment innate immunity for tissue-wide antiviral protection (2016) (0)
Response : The role of antiviral agents in the treatment of multicentric Castleman disease (2004) (0)
Author response: Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract (2012) (0)
Concepts in the Development of Vaccines Against Genital Herpes Simplex Virus Infections (1985) (0)
T Cells + CD4Lymphoblastoid B Cell Lines to Stimulate Herpes Simplex Inhibits the Capacity of (2001) (0)
Author response: Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract (2012) (0)
Antiviral chemotherapy 4 : new directions for clincal application and rersearch (2017) (0)
HHV‐8: Anatomic Sites, Shedding Patterns, Behavioral and Biological Risk Factors for Transmission.: ABSTRACT S10 (2000) (0)
Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones (2000) (0)
DELAYED PRODUCTION OF INTERFERON-GAMMA (IFNγ) AND TUMOR NECROSIS FACTOR (TNFα) BY MONONUCLEAR CELLS (MC) OF HERPES SIMPLEX VIRUS (HSV) INFECTED NEONATES (NB) (1987) (0)
Plasma and CSF herpes simplex virus levels at diagnosis and outcome of neonatal infection (2015) (0)
P11-17. Intermittent rectal shedding of multiple human adenovirus serotypes among HIV-positive MSM (2009) (0)
voriconazole treatment Improved outcome in central nervous system aspergillosis, using (2013) (0)
Annals of Internal Medicine (1996) (0)
Preliminary safety and activity evaluation of new agents for the treatment of HIV-1 infection: Recommended guidelines for trial design (1992) (0)
Clinical perspectives in the treatment of HIV disease: the role of didanosine. Introduction. (1993) (0)
Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children (2017) (0)
Is viral shedding a surrogate marker for transmission of genital herpes? Introduction (2004) (0)
InfectionControl of Chronic Human Herpesvirus 8 T Cells Involvement in Viral Immune + (2008) (0)
SARS-CoV-2 neutralizing-antibody responses in convalescent individuals in US and Peru (2021) (0)
HumanHerpesvirus 6DNA inPeripheral BloodCells and Saliva fromImmunocompetent Individuals (1993) (0)
P3-S2.03 Clinical evaluation of the BD HSV1 Qx assay for the direct qualitative testing of HSV1 as compared to viral culture and a laboratory-based PCR assay using male and female external anogenital lesions (2011) (0)
Contributors (2015) (0)
Impact of neutralizing antibody to respiratory syncytial virus (RSV) on respiratory disease progression in hematopoietic stem cell transplant recipients (HCT) (2006) (0)
A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients. (2007) (0)
Baeten Genital HIV-1 RNA Predicts Risk of Heterosexual HIV-1 Transmission (2011) (0)
Enterovirus RNA in Cerebrospinal Fluid Liquid-Phase Hybridization for Detection of Evaluation of Real-Time PCR versus PCR with (2003) (0)
rebound VZV disease after drug discontinuation disease following hematopoietic cell transplantation: no evidence of One-year acyclovir prophylaxis for preventing varicella-zoster virus (VZV) (2013) (0)
80: Primary CMV Infection in CMV Seronegative Recipients of a Stem Cell Product from a Seropositive Donor (D+/R-): Frequency of and Risk Factors for Transmission (2008) (0)
In Vivo Inhibition of Type I Interferon Transcription in Genital HSV-2 Lesions (134.72) (2009) (0)
Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study. (2022) (0)
Antibody toherpes simplex virus type2asserological markerof sexual lifestyle inpopulations (1994) (0)
53 Long-term suppressive acyclovir (ACV) use reduces Varicella zoster (VZV) diseases and emergence of ACV-resistant herpes simplex viruses (HSV) after stem cell transplantation (HCT) (2006) (0)
reprogramming of the primary immune response by T cell receptor antagonism (2004) (0)
C6/36 cells are unable to produce a Dicer-2-like product. (2013) (0)
Effect of aciclovir on HIV-1 acquisition in HSV-2-positive patients – Authors' reply (2008) (0)
In Memoriam: Stephen Sacks (2004) (0)
Topical Treatment ofInfection withAcyclovir-Resist ant Mucocutaneous HerpesSimplex Viruswith theRibonucleotide Reductase Inhibitor 348U87 inCombination withAcyclovir (1993) (0)
Evaluation of a Novel Viral Load Based Surveillance Strategy for Prevention of Cytomegalovirus (CMV) Disease in Hematopoietic Cell Transplantation (2011) (0)
Poor immunogenicity as the reason for the ineffectiveness of a glycoprotein subunit vaccine for genital herpes (1989) (0)
A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue (2021) (0)
P3-S2.04 Clinical evaluation of the BD HSV2 Qx assay for the direct qualitative testing of HSV2 as compared to viral culture and a laboratory-based PCR assay using male and female external anogenital lesions (2011) (0)
HLA A*01 and B*08 are associated with increased genital shredding of HSV-2 (2009) (0)
Incidence of Neonatal Herpes Simplex Infections-Reply (1985) (0)
The Herpesviruses (1985) (0)
INFECTIOUS DISEASES: Genital Herpes Recurrence Rates (1999) (0)
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation (2021) (0)
A meta-analysis of passive immunization studies shows an association of serum neutralizing antibody titer with protection against SHIV challenge (2019) (0)
Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. (2023) (0)
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine (2023) (0)
Antigenic Specificities ofHumanCD4+T-Cell Clones Recovered fromRecurrent Genital HerpesSimplex Virus Type2Lesions (1994) (0)
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens (2020) (0)
HSV-2 and HIV (1997) (0)
COVID-19 vaccination and HIV-1 acquisition – Authors’ reply (2022) (0)
Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19 (2022) (0)
Human Herpesvirus 6B and Pulmonary Disease after Hematopoietic Cell Transplantation (2019) (0)
Using Haplotype-Based Artificial Intelligence to Evaluate SARS-CoV-2 Novel Variants and Mutations (2023) (0)
Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition (2022) (0)
Membrane-associated antigens of herpes simplex virus. Discussion (1991) (0)
Detection of Kaposis sarcoma associated herpesvirus in saliva of human immunodeficiency virus infected individuals with and without Kaposis sarcoma (1996) (0)
Cesarean Delivery in Women With Genital Herpes (1997) (0)
HIV vaccine effectiveness and the mucosal interface (2007) (0)
What constitutes successful therapeutic strategies for genital herpes (2000) (0)
subclinical reactivation stem cell transplantation: impact of host factors, drug therapy, and Immune reconstitution to cytomegalovirus after allogeneic hematopoietic (2013) (0)
Molecular weight variability in the terminal and joint fragments of bam h i digests of herpes simplex virus type 2 dna is eliminated by double digestion with bam h i and pvu i i (1987) (0)
Characteristics of Primary HIV Infection (1999) (0)
Effect of Pritelivir ComparedWith Valacyclovir on Genital HSV-2 Shedding in PatientsWith Frequent Recurrences (2017) (0)
Interferon-Gamma for Human Papillomavirus Infection (2020) (0)
Lawrence Corey Immunobiology and Vaccine Research Recent Progress in Herpes Simplex Virus (2002) (0)
P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be? (2009) (0)
General Obstetrics and Gynecology-Gynecology-Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type (2000) (0)
Author Correction: A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue (2021) (0)
Topical Idoxuridine in the Treatment of Genital Herpes-Reply (1983) (0)
Genital Herpes and Erythema Multiforme-Reply (1983) (0)
HLA targeting efficiency correlates with human T-cell responses magnitude and with mortality from Influenza-A infection (105.30) (2012) (0)
Lack of detection of HSV DNA in PBMCs and lymph nodes of HIV-infected persons. (1996) (0)
N t-lymphocytes and thus identified hsv-antigenic (2003) (0)
Reduced T-cell Infiltration at Site of Herpes Simplex Virus (HSV) Reactivation in Controlled HIV (2016) (0)
CD277 reduces B cell Activation by HIV Env Immunogens (2016) (0)
CLINICAL AND LABORATORY OBSERVATIONS (1983) (0)
Development of flow cytometry‐based assays to assess the ability of antibodies to bind to SARS‐CoV‐2‐infected and spike‐transfected cells and mediate NK cell degranulation (2022) (0)
282 HERPES SIMPLEX VIRUS-INFECTED CELLS INACTIVATE CYTOTOXIC T LYMPHOCYTES: INSIGHT INTO A NOVEL IMMUNE EVASION MECHANISM. (2004) (0)
Comparison ofNeutralization andDNA Restriction Enzyme MethodsforTyping Clinical Isolates ofHuman Adenovirus (1985) (0)
In reply [6] (2006) (0)
Granzyme B or Fas Activation and Apoptosis Induced by HSV and Glycoprotein J Inhibit Caspase (2001) (0)
Factors affecting the transmission rates of genital herpes: considerations for designing vaccine field trials (1989) (0)
AIDS and HIV infection. (1990) (0)
Recent Advances in the Diagnosis of Hepatitis (1980) (0)
Improved outcome in CNS aspergillosis, using voriconazole [5] (2006) (0)
Detection of Adeno-Associated Virus (AAV) Viremia in Hematopoietic Cell Transplant (HCT) Recipients (2007) (0)
Development of anti-PD-1 chimeric antigen receptor T cells to target a PD-1+ CD4 T cell population enriched in HIV provirus (2019) (0)
Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial (2022) (0)
O3-S5.01 Impact of AIC316, a novel antiviral helicase-primase inhibitor, on genital HSV shedding: randomised, double-blind, placebo-controlled trial (2011) (0)
CHARACTERISTICS OF PRIMARY HIV INFECTION. AUTHORS' REPLY (1999) (0)

This paper list is powered by the following services:

Other Resources About Lawrence Corey

What Schools Are Affiliated With Lawrence Corey?

Lawrence Corey is affiliated with the following schools:

Lawrence Corey's Academic­Influence.com Rankings

Why Is Lawrence Corey Influential?

Lawrence Corey's Published Works

Published Works

Other Resources About Lawrence Corey

What Schools Are Affiliated With Lawrence Corey?

Lawrence Corey's AcademicInfluence.com Rankings